Researchers in Israel have developed a liquid biopsy blood test that detects early-stage lung cancer with over 90% accuracy. Published in npj Precision Oncology, the method uses light waves to identify chemical signatures of circulating cell-free DNA, offering a faster and more economical diagnostic alternative to traditional sequencing.
Lung cancer remains the most lethal cancer in the world. Conventional screening methods, primarily low-dose computed tomography (CT) scans, often produce false positives that can lead to unnecessary follow-up procedures.
In Plain English: The Clinical Takeaway
- Liquid Biopsy Mechanism: The test detects cell-free DNA—genetic material shed by tumors into the bloodstream—using optical light waves rather than complex gene sequencing.
- Tumor Differentiation: Laboratory trials demonstrated the assay’s capability to distinguish between non-small cell lung cancer and the more aggressive small cell lung cancer.
- Complementary Utility: Medical experts stress that the technology is intended to supplement, not replace, existing diagnostics like low-dose CT scans.
Optical Precision and Laboratory Findings
Instead of mapping entire genetic sequences via costly computational pipelines, the Tel Aviv University team utilized optical waves to analyze the chemical fingerprints of cell-free DNA.
In laboratory evaluations detailed in npj Precision Oncology, this optical biopsy approach achieved an accuracy exceeding 90 percent. Furthermore, the assay successfully differentiated non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC), a more aggressive subtype.
| Diagnostic Parameter | Low-Dose CT Scans | New Optical Liquid Biopsy (Tel Aviv University) |
|---|---|---|
| Primary Modality | Radiological imaging | Optical analysis of circulating cell-free DNA |
| Accuracy Rate | Standard tool | Reported over 90% accuracy in lab testing |
| False Positive Risk | Known to produce false positives requiring follow-ups | Aims to reduce unnecessary invasive procedures |
| Subtype Differentiation | Standard tool | Differentiates NSCLC and SCLC in initial testing |
While the diagnostic statistics are encouraging, investigators emphasize that the technology remains in a preliminary phase. Extensive clinical validation trials are required before the analysis can be incorporated into habitual medical practice.
Beyond initial screening, the research team anticipates that optical liquid biopsies could eventually be deployed to monitor patient therapeutic response over time.
Smoking remains the primary risk factor for lung cancer, though environmental pollution, exposure to carcinogens, and genetic predispositions also contribute.
Contraindications & When to Consult a Doctor
Individuals who meet high-risk criteria—such as a heavy smoking history—should continue to undergo low-dose CT scans as recommended.
References
- Tel Aviv University & Collaborators. Study on optical liquid biopsy for lung cancer detection. npj Precision Oncology.
Disclaimer: This article provides medical journalism for informational purposes only. This article does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional for personal medical concerns.
